161 related articles for article (PubMed ID: 25339454)
21. Implication of ¹⁸F-Fluorodeoxyglucose Uptake of Affected Axillary Lymph Nodes in Cases with Breast Cancer.
Fujii T; Yajima R; Tatsuki H; Oosone K; Kuwano H
Anticancer Res; 2016 Jan; 36(1):393-7. PubMed ID: 26722071
[TBL] [Abstract][Full Text] [Related]
22. Correlations between dual-phase 18F-FDG uptake and clinicopathologic and biological markers of breast cancer.
Kaida H; Azuma K; Toh U; Kawahara A; Sadashima E; Hattori S; Akiba J; Tahara N; Rominger A; Ishii K; Murakami T; Ishibashi M
Hell J Nucl Med; 2018; 21(1):35-42. PubMed ID: 29550845
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic accuracy of 18F-2-deoxy-fluoro-D-glucose positron emission tomography for pN1 lymph nodes in patients with lung cancer.
Nakagawa M; Hara M; Sakurai K; Ozawa Y; Mizuno A; Tamaki T; Nishio M; Shibamoto Y
Acta Radiol; 2009 Jul; 50(6):638-44. PubMed ID: 19492198
[TBL] [Abstract][Full Text] [Related]
24. [The role of FDG-PET-CT in the evaluation of primary systemic therapy in breast cancer: links between metabolic and pathological remission].
Tőkés T; Somlai K; Székely B; Kulka J; Szentmártoni G; Torgyík L; Galgóczy H; Lengyel Z; Györke T; Dank M
Orv Hetil; 2012 Dec; 153(49):1958-64. PubMed ID: 23204302
[TBL] [Abstract][Full Text] [Related]
25. Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors.
Ikenaga N; Otomo N; Toyofuku A; Ueda Y; Toyoda K; Hayashi T; Nishikawa K; Tanaka M
Am Surg; 2007 Nov; 73(11):1151-7. PubMed ID: 18092653
[TBL] [Abstract][Full Text] [Related]
26. Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-Deoxy-2-fluoro-D-glucose-positron emission tomography.
Inoue T; Yutani K; Taguchi T; Tamaki Y; Shiba E; Noguchi S
J Cancer Res Clin Oncol; 2004 May; 130(5):273-8. PubMed ID: 14986112
[TBL] [Abstract][Full Text] [Related]
27. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures.
Fuster D; Duch J; Paredes P; Velasco M; Muñoz M; Santamaría G; Fontanillas M; Pons F
J Clin Oncol; 2008 Oct; 26(29):4746-51. PubMed ID: 18695254
[TBL] [Abstract][Full Text] [Related]
28. Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer.
Gil-Rendo A; Zornoza G; García-Velloso MJ; Regueira FM; Beorlegui C; Cervera M
Br J Surg; 2006 Jun; 93(6):707-12. PubMed ID: 16622900
[TBL] [Abstract][Full Text] [Related]
29. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group.
Wahl RL; Siegel BA; Coleman RE; Gatsonis CG;
J Clin Oncol; 2004 Jan; 22(2):277-85. PubMed ID: 14722036
[TBL] [Abstract][Full Text] [Related]
30. Lymphoscintigraphy in breast cancer patients after neoadjuvant chemotherapy. Diagnostic value and the work-up of sentinel node negative patients.
Dalus K; Reitsamer R; Holzmannhofer J; Rendl G; Pirich C; Kronberger C; Rettenbacher L
Nuklearmedizin; 2011; 50(1):33-8. PubMed ID: 21336417
[TBL] [Abstract][Full Text] [Related]
31. Prediction of lymph node status in clinical stage IA squamous cell carcinoma of the lung.
Tsutani Y; Murakami S; Miyata Y; Nakayama H; Yoshimura M; Okada M
Eur J Cardiothorac Surg; 2015 Jun; 47(6):1022-6. PubMed ID: 25293403
[TBL] [Abstract][Full Text] [Related]
32. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited.
Zhang X; Wu F; Han P
Hell J Nucl Med; 2014; 17(3):177-83. PubMed ID: 25526754
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET.
Adler LP; Crowe JP; al-Kaisi NK; Sunshine JL
Radiology; 1993 Jun; 187(3):743-50. PubMed ID: 8497624
[TBL] [Abstract][Full Text] [Related]
34. Chest wall and axillary lymph node FDG uptake associated with cancer vaccine therapy for lung cancer.
Kaneko K; Yoshida T; Hiyama J; Ono K; Omagari J
Clin Nucl Med; 2010 Sep; 35(9):729-30. PubMed ID: 20706056
[TBL] [Abstract][Full Text] [Related]
35. Tumour 18 F-FDG Uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes.
Kim JY; Lee SH; Kim S; Kang T; Bae YT
Eur Radiol; 2015 Apr; 25(4):1172-81. PubMed ID: 25298170
[TBL] [Abstract][Full Text] [Related]
36. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.
Koolen BB; Valdés Olmos RA; Elkhuizen PH; Vogel WV; Vrancken Peeters MJ; Rodenhuis S; Rutgers EJ
Breast Cancer Res Treat; 2012 Aug; 135(1):231-40. PubMed ID: 22872522
[TBL] [Abstract][Full Text] [Related]
37. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters.
Buck A; Schirrmeister H; Kühn T; Shen C; Kalker T; Kotzerke J; Dankerl A; Glatting G; Reske S; Mattfeldt T
Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1317-23. PubMed ID: 12271413
[TBL] [Abstract][Full Text] [Related]
38. Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer.
Kidd EA; Siegel BA; Dehdashti F; Grigsby PW
Cancer; 2010 Mar; 116(6):1469-75. PubMed ID: 20108309
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the diagnostic value of 3-deoxy-3-18F-fluorothymidine and 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of regional lymph node in thoracic esophageal squamous cell carcinoma: a pilot study.
Han D; Yu J; Zhong X; Fu Z; Mu D; Zhang B; Xu G; Yang W; Zhao S
Dis Esophagus; 2012 Jul; 25(5):416-26. PubMed ID: 21951837
[TBL] [Abstract][Full Text] [Related]
40. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]